<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="257">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059158</url>
  </required_header>
  <id_info>
    <org_study_id>18-606</org_study_id>
    <secondary_id>18-606</secondary_id>
    <secondary_id>1081</secondary_id>
    <nct_id>NCT05059158</nct_id>
  </id_info>
  <brief_title>Amyloid-β Clearance Mechanisms in Alzheimer's Disease</brief_title>
  <acronym>AmyClearAD</acronym>
  <official_title>Amyloid-β Clearance Mechanisms: A Multi-modal Study on Lymphatic, Glymphatic and Blood-brain-barrier Function in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the&#xD;
      blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation.&#xD;
      In order to achieve this aim the investigators intend to study participants with a Subjective&#xD;
      Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators want to examine the different mechanisms of the accumulation&#xD;
      and the clearance of Aß- deposits with imaging methods. One focus of the study is an improved&#xD;
      characterisation of a blood-brain-barrier disorder (which seems to have an impact on the&#xD;
      Aß-accumulation). Another main aim is to provide an improved mechanistic clearance model,&#xD;
      which integrates crucial components such as the recently proposed cerebral glymphatic and&#xD;
      lymphatic pathways, and which addresses the interaction between the different components and&#xD;
      their individual contribution to Aβ removal from the brain. A possible connection between&#xD;
      sleep and an altered transport mechanism will be analysed. The prospective study cohort (N&#xD;
      ~60) will include patients with Mild Cognitive Impairment, mild clinical AD and Subjective&#xD;
      Cognitive Decline. All study participants will undergo a detailed clinical and&#xD;
      neuropsychological assessment according to a standardised protocol (i.a. MRI, PET, CSF,&#xD;
      actigraphy). Follow-up assessments will not be performed in the present project, but are&#xD;
      planned in a subsequent study, pending further funding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in the disruption of the brain-blood-barrier between the subgroups</measure>
    <time_frame>Baseline</time_frame>
    <description>Name of Measurement: Ktrans; Measurement Tool: DCI sequence (MRI); Unit: min -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance mechanisms and glymphatic or cerebral lymphatic system</measure>
    <time_frame>Baseline</time_frame>
    <description>Can a disruption in the cerebral clearance through the glymphatic or cerebral lymphatic system be proven in patients with AD, MCI or SCD?&#xD;
Name of Measurement: DTI ALPS; Measurement Tool: DTI MRI; Unit: mean (Dxpro, Dypro)/ mean (Dypro, Dzasc)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Connection between the structural/functional connectivity of the resting networks and the clearance mechanisms</measure>
    <time_frame>Baseline</time_frame>
    <description>Correlations between correlations of bold fluctuations/ number of tracts and DTI ALPS Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences between sleep and activity in SCD, MCI and AD; Do they have a mediator role in association of the BBB disruption and Aß pathology?</measure>
    <time_frame>Baseline</time_frame>
    <description>Name of Measurement: Sleep Efficiency, Sleep Time, PIM, TAT, ZCM ;Measurement Tool: Actigraphy; Units: minutes, count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Connection between clinical symptoms, Aß pathology and BBB disorder</measure>
    <time_frame>Baseline</time_frame>
    <description>Correlations between Clinical Dementia Rating Sum of Boxes, CSF markers (pg/ml) and Aß PET, SUVr and Ktrans map</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <description>Patients with a Alzheimer's Disease diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <description>Patients with a mild cognitive impairment diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjective Cognitive Decline</arm_group_label>
    <description>Patients with a subjective cognitive decline diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>positron emission tomography (PET)</intervention_name>
    <description>18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.</description>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>Subjective Cognitive Decline</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        SCD, MCI or AD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of amnestic MCI or AD dementia or clinical normal&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Unchanged pharmacotherapy within 4 days prior to the study specific assessments&#xD;
&#xD;
          -  Fluent in German&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent or has a legal guardian&#xD;
&#xD;
          -  Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder&#xD;
&#xD;
          -  Clinically relevant depression&#xD;
&#xD;
          -  Acute suicidality&#xD;
&#xD;
          -  Current alcohol, drug or medication abuse&#xD;
&#xD;
          -  History of severe traumatic brain injury within 3 months prior to inclusion&#xD;
&#xD;
          -  Structural lesions of the basal ganglia or brain stem&#xD;
&#xD;
          -  Severe neurological disorder including (but not limited to) epilepsy, systemic&#xD;
             disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial&#xD;
             pressure, normal pressure hydrocephalus&#xD;
&#xD;
          -  Severe medical disorders including (but not limited to) heart failure, respiratory&#xD;
             failure, uncontrolled severe arterial hypertension&#xD;
&#xD;
          -  Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication&#xD;
&#xD;
          -  Renal failure &gt; stage 3 (GFR &lt; 30 mL/min)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unresolved malignancies within two years prior to inclusion&#xD;
&#xD;
          -  Severe current infections or other chronic or systemic disorders&#xD;
&#xD;
          -  Other circumstances which preclude participation based on the investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Perneczky, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Perneczky, Prof.Dr.med.</last_name>
    <phone>+4989440055863</phone>
    <email>PSY.Alzheimerzentrum@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lena Burow, M.Sc.</last_name>
    <phone>+4989440055898</phone>
    <email>lena.burow@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Perneczky, Prof. Dr.</last_name>
      <phone>+49 89 4400 55863</phone>
      <email>PSY.Alzheimerzentrum@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Lena Burow, M.Sc.</last_name>
      <phone>+49 89 4400 55898</phone>
      <email>lena.burow@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Carolin Kurz, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris-Stephan Rauchmann, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Selim Gürsel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Brendel, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Robert Perneczky</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Sleep</keyword>
  <keyword>Actigraphy</keyword>
  <keyword>Blood-brain-barrier</keyword>
  <keyword>Amyloid-β Clearance Mechanisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

